PYC Chart and Technical Analysis, page-105

Hey Hot and Medic and anyone else with an opinion,

I note Rett Syndrome has a prevelance of 1:10-15000 girls ie 1:20-30000 population. Our likely first commerical product is RP11 around a third to a quarter of that at 1:100000. So I’m making a basic possibly poor assumption that Rett was a 3-4 billion market as opposed to RP11 1 billion.

If PYC did a deal on this product is it likely to give us enough momentum to allow the other products to develop relatively unimpeded financially? Looking at PYC timetable that would be ADOA followed by PKD then PMS. Glaucoma also gets a mention in our latest presentation.

Any thoughts I’m not particularly commercially savy so would appreciate any input. Feel free to dum it down. Not really looking for a share price as I feel that is a snapshot in time and I’m hoping for an upward trend.
Eagle